Algenpantucel-L - NewLink Genetics Corporation

Drug Profile

Algenpantucel-L - NewLink Genetics Corporation

Alternative Names: HAPa; HyperAcute Pancreas; HyperAcute-Pancreas-Immunotherapy; Pancreatic cancer vaccine - NewLink Genetics

Latest Information Update: 18 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies; DNA vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer

Most Recent Events

  • 30 Jun 2016 NewLink Genetics terminates a phase II trial in Pancreatic cancer (Combination therapy) in USA (NCT02405585)
  • 09 May 2016 NewLink Genetics does not meet the primary endpoint in a phase III IMPRESS trial in Pancreatic cancer
  • 15 Dec 2015 NewLink Genetics completes enrolment in the phase III PILLAR trial in Pancreatic cancer (Combination therapy, Inoperable/Unresectable) in USA (NCT01836432)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top